Research

The project and development of the software will be followed by a real testing on the clinic case selected within this project, the Metabolic Syndrome (MS).

The project and development of the software will be followed by a real testing on the clinic case selected within this project, the Metabolic Syndrome (MS).

The research aims to arguing the item that lots of recent studies have shown: the close relationship between the intestinal microbiota and the metabolic disorders.

As a matter of fact, we have observed a remarkable difference in the composition of the intestinal flora among normal weight and obese subjects. The composition of the intestinal flora is easily mutable and this allows the development of a targeted therapy that should allow antibiotics, prebiotics and probiotics.

On the basis of these premises, the testing of the INNOMA project will be addressed to the identification of the composition of the microbiota of healthy subjects and affected by Metabolic Syndrome through the collection of salivary and faecal samples.

Hence, we will create software in order to:

  • plan new diagnostic and predictive tests and realize new probiotics and/or new functional food with preventive features of MS;
  • support the diagnostic and therapeutic activities;
  • supply monitoring systems of the specific pathology on the territory;
  • make the communication physician-patient more rapid and appropriate.

Hence, it will be a true (DSS), useful to obtain some sophisticated data for the development of new products and to improve the activities of prevention and treatment of Metabolic Syndromes.

The design, development and testing of the software will occur in Openlab mode.

Moreover, the cooperation among the several professionals dealing with this project and the huge data collection, will allow:

the sharing of skills, experiences and technologies among enterprises in order to “create a critical mass” more and more oriented to meet the needs of the citizen;

the transfer of know-how, within the “omics” sciences, on the part of the public laboratory being part of the group, and its acquisition not only from the enterprises but also from the final users, that is hospitals, food farming companies and pharmaceutical companies.

Questo sito fa uso di cookie per migliorare l’esperienza di navigazione degli utenti e per raccogliere informazioni sull’utilizzo del sito stesso. Può conoscere i dettagli consultando la nostra cookie policy.